Gene deficiency or pharmacological inhibition of PDCD4-mediated FGR signaling protects against acute kidney injury

Xu Jing\textsuperscript{a,d,1}, Dandan Ren\textsuperscript{a,e,1}, Fei Gao\textsuperscript{b,1}, Ye Chen\textsuperscript{a}, Xiao Wu\textsuperscript{b}, Yue Han\textsuperscript{a}, Qingsheng Han\textsuperscript{a}, Liang Li\textsuperscript{a}, Xiaojie Wang\textsuperscript{a}, Wei Tang\textsuperscript{c}, Yan Zhang\textsuperscript{a,}\ast

\textsuperscript{a}Department of Pharmacology, School of Basic Medical Science, Shandong University, Jinan 250012, China
\textsuperscript{b}The Key Laboratory of Cardiovascular Remodeling and Function Research, Department of Cardiology, Qilu Hospital of Shandong University, Jinan 250012, China
\textsuperscript{c}Department of Microbiology, School of Basic Medical Science, Shandong University, Jinan 250012, China
\textsuperscript{d}Department of Clinical Laboratory, the Second Hospital of Shandong University, Jinan 250033, China
\textsuperscript{e}Chengda Biology Co., Ltd., Shenyang 110179, China

Received 2 August 2020; received in revised form 23 September 2020; accepted 13 October 2020

\textbf{KEYWORDS}
Acute kidney injury; Ischemia—reperfusion injury; PDCD4; Cell death; Tyrosine kinase; FGR; NOTCH1; Inflammation

\textbf{Abstract} Recent studies have shown that programmed cell death 4 (PDCD4) modulates distinct signal transduction pathways in different pathological conditions. Despite acute and chronic immune responses elicited by ischemia contributing to the functional deterioration of the kidney, the contributions and mechanisms of PDCD4 in acute kidney injury (AKI) have remained unclear. Using two murine AKI models including renal ischemia/reperfusion injury (IRI) and cisplatin-induced AKI, we found that PDCD4 deficiency markedly ameliorated renal dysfunction and inflammatory responses in AKI mice. Consistently, upregulation of PDCD4 was also confirmed in the kidneys from patients with biopsy confirmed acute tubular necrosis from a retrospective cohort study. Moreover, we found that overexpression of Fgr, a member of the tyrosine kinase family, dramatically aggravated renal injury and counteracted the protective effects of PDCD4 deficiency in AKI mice. We discovered that FGR upregulated NOTCH1 expression through activating STAT3. Most importantly, we further found that systemic administration of ponatinib, a tyrosine kinase inhibitor, significantly ameliorated renal dysfunction and inflammatory responses in AKI mice. In summary, we identified that PDCD4 served as an important regulator, at least in part, of FGR/NOTCH1-mediated tubular apoptosis and inflammation in AKI mice. Furthermore, our findings suggest that ponatinib-
Acute kidney injury (AKI) is a common complication with high morbidity and mortality worldwide, which is often induced by ischemia/reperfusion injury (IRI), sepsis or toxins. During the process of AKI, the tubular epithelial cells (TEC) is not merely a passive victim of injury as evidenced by mitochondrial dysfunction, ATP depletion, impaired solute/ion transport, loss of cellular polarity, cytoskeletal disruption, and cell death, but also an active participant in inflammatory responses in AKI. Therefore, a better understanding of the molecular and cellular aspects underlying tubular epithelium injury has important therapeutic implications for treating AKI patients.

Programmed cell death 4 (PDCD4) is expressed ubiquitously in different tissues, and is a multifunctional tumor suppressor that inhibits cellular growth, tumor invasion, metastasis and induction of apoptosis. The expression of PDCD4 is often downregulated in tumors but is maintained at high levels in a large number of diseases. PDCD4 has been considered as a potential target for anticancer therapies in recent years. Recently, emerging evidence has also shown that PDCD4 can affect gene transcription and can also inhibit protein translation via two distinct mechanisms. One of these mechanisms acts in a translation-initiation-factor-4A (eIF4A)-dependent manner. By binding competitively to eIF4A, PDCD4 inhibits the combination of the RNA helicase, eIF4A, and the scaffold protein, eIF4G, which initiates the translation of mRNA. In addition to this eIF4A-dependent mechanism, PDCD4 may directly bind to mRNAs such as those encoding antiapoptotic proteins, BCL-XL, and X-chromosome-linked inhibitor of apoptosis (XIAP), to suppress their translation. Several studies have reported that PDCD4 is involved in the induction of inflammation. PDCD4 has been found to be involved in macrophage- and T-cell-mediated immune responses. Other studies have indicated that PDCD4 can inhibit the production of IL-10 through the Twist2/c-MAF pathway. Furthermore, Pdcd4-deficient mice are resistant to the induction of inflammatory diseases such as autoimmune encephalomyelitis and diabetes, indicating that PDCD4 regulates both carcinogenesis and inflammation. In atherosclerosis, PDCD4 increases both the formation of foam cells and the release of inflammatory mediators. Despite acute and chronic immune responses elicited by ischemia or toxicity contributing to the functional deterioration of the kidney, the contributions and mechanisms of PDCD4 to AKI have remained unclear.

Overactivation of NOTCH1 signaling results in a series of pathological consequences, including the formation of different types of tumors. In addition to these effects, activated NOTCH1 signaling is also reported to contribute to kidney fibrosis and is involved in the podocytic injury, indicating its important role in the kidney. In injured cells, NOTCH1 signaling is activated through the binding of the ligand, Jagged, to its membrane receptor. The NOTCH1 intracellular domain is an active intracellular domain of NOTCH1 and translocates to the nucleus to stimulate signaling cascades. In the present study, we found that PDCD4 deficiency protected against the model of AKI in mice, at least in part, by regulating FGR/NOTCH1-mediated apoptosis and immune responses. Importantly, we further found that systemic administration of ponatinib, a third-generation tyrosine kinase inhibitor, significantly ameliorated AKI in mice. Taken together, our findings suggest that a better understanding of the biological activities of PDCD4 may provide unexpected opportunities for developing novel therapies for ameliorating AKI.

### 2. Materials and methods

Procedures for detailed mouse models of AKI, RNA extraction, real-time reverse-transcription polymerase chain reaction (RT-PCR), Western blot analysis, assessment of renal function, immunohistochemistry, morphological examinations, caspase-3 activity assays and luciferase reporter assays were presented online in the Supporting Information.

#### 2.1. Animal studies and drug treatments

Twelve-week-old male Pdcd4-deficient mice (20–25 g) in C57BL/6 background were obtained from ViewSolid Biotech (Beijing, China). Experiment mice were randomly divided into different groups using a random-block grouping. When assessing the outcome and analysis of the results, a double-blind method was employed. AKI was induced by renal IRI or cisplatin as described previously, and the detailed procedures can be found in our online supplemental materials. The experiments were also designed to evaluate the preventive and potential therapeutic effects of ponatinib on AKI. Mice received ponatinib (15 mg/kg, i.p., Selleckchem, Houston, TX, USA) at 6 h before the induction of ischemia; the vehicle group received an equal volume of vehicle (DMSO:PEG300:Tween80:NS = at a ratio of 1:6:1:33). All protocols were approved by the Medical Ethics Committee of Medical School Shandong University (201401049) and were conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

#### 2.2. Cell culture and treatments

Immortalized rat renal proximal tubule (NRK-52E) cells, human podocytes (HPC), glomerular endothelial cells (GENC), and glomerular mesangial cells (RMC) were cultured and treated as described previously. These cells were certified using short-tandem-repeat genotyping and were tested for mycoplasma contamination once per month.
2.3. Flow cytometry

Cell apoptosis was determined by 7AAD-Annexin V staining as described previously16.

2.4. Immunofluorescent staining and confocal microscopy

Immunofluorescent staining was performed as described previously20. We used a LSM780 laser-scanning confocal microscope (ZEISS, Germany) equipped with a Plan-Apochromat 63/1.4 objective for all imaging.

2.5. Intrarenal adeno-associated virus (AAV) delivery

Overexpression of adeno-associated virus (AAV) constructs of Fgr (rAAV9-Fgr-GFP) and their negative controls (rAAV9-GFP) was designed and purchased from ViGene Biosciences (Shandong, China). The titers of rAAV9-GFP and rAAV9-Fgr-GFP were approximately $8.0 \times 10^{12}$ viral genomes/mL and $6 \times 10^{11}$ viral genomes/L of rAAV9-Fgr-GFP or rAAV9-GFP were delivered to the kidney by means of intraparenchymal injections. The procedure for intraparenchymal delivery was performed as described previously19,21. Preliminary studies indicated that AAV-mediated GFP protein expression in the kidney parenchyma was significantly increased after one month, and no toxicity was observed in AAV-treated mice.

2.6. Statistical analysis

Data are presented as mean ± standard deviation (SD). Statistically significant differences between the control group and treated groups were determined by one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s test that was carried out via GraphPad Prism 8.0. Differences among multiple groups were examined by Tukey’s multiple comparison test via GraphPad Prism 8.0. $P < 0.05$ was considered statistically significant.

3. Results

3.1. PDCD4 expression is significantly induced in the kidneys of renal IRI mice

First, we found that PDCD4 was expressed in various tissues and in different renal parenchymal cells including rat glomerular mesangial cells (RMC), rat glomerular endothelial cells (GENC), human podocytes (HPC) and rat proximal tubule epithelial cells (NRK-52E cells, Supporting Information Fig. S1). We further observed that the expression of PDCD4 was time-dependently induced in the kidney after 45 min of renal ischemia followed by different time points of reperfusion, as indicated by real-time RT-PCR (Fig. 1A) and Western blot (Fig. 1B) analyses; these findings were also confirmed in paraffin-embedded sections of renal tissues via immunohistochemical (IHC) staining (Fig. 1C). To define the tubular segment-specific increase of PDCD4 expression in the kidneys from mice with renal IRI, we used double immunostaining for PDCD4 (green) and various tubular markers (red) in the kidney. As shown in Supporting Information Fig. S2, PDCD4 was mainly expressed and induced in proximal tubules and collecting ducts. Importantly, we found that compared with renal tissues obtained from patients who underwent tumor nephrectomies without other renal disease, PDCD4 was also upregulated in the kidney from patients with biopsy-confirmed acute tubular necrosis, which presents with AKI and is one of the most common causes of AKI (Fig. 1D).

3.2. Pdcd4 deficiency ameliorates renal IRI in mice

Pdcd4−/− mice were phenotypically normal and had no appreciable defects in renal morphology or function. However, Pdcd4
deficiency in mice significantly ameliorated renal IRI, as evidenced by a reduction of serum creatinine (Fig. 2A) and blood urea nitrogen (BUN, Fig. 2B), mitigated morphological injury (Fig. 2C and D), and reduced cell death as demonstrated by terminal deoxynucleotidyl transferase-mediated digoxigenin-dUTP nick-end labeling (TUNEL) staining (Fig. 2E and F). In addition, Pdcd4 deficiency also reduced inflammatory responses by decreasing the levels of pro-inflammatory mediators.

Figure 2  PDCD4 deficiency ameliorates renal IRI in mice. (A) Serum creatinine (Scr) concentrations in different groups of mice. (B) BUN levels in different groups of mice. (C) Representative micrographs showing the morphology of the kidneys from different groups of mice. (D) Quantitative assessment of tubular damage. (E) In situ TUNEL assays were performed to assess renal cell death. Nuclei were revealed using DAPI staining. (F) Quantitative assessment of the number of dead cells (numbers per high-power field [HPF]). (G) The mRNA levels of pro-inflammatory mediators including Il-1β, Tnf-α, Il-6, and monocyte chemotactic protein-1 (Mcp-1) in the kidneys from different groups of mice. (H) Representative sections of kidneys stained for macrophages (CD68) and neutrophils (Ly6B) from different groups of mice. (I) Data analysis of macrophage and neutrophil infiltrates in the kidneys (numbers per high-power field [HPF]) from different groups of mice. All data are displayed as mean ± SD, n = 8; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA.
(Fig. 2G), as well as macrophage and neutrophil (Fig. 2H and I) infiltration in the kidneys from mice with renal IRI.

### 3.3. PDCD4 positively regulates FGR expression

Using Agilent Whole-Mouse-Genome Oligo Microarrays for global gene expression analysis, we found that IRI-induced the expression of FGR, a member of the SRC family of non-receptor tyrosine kinases, but was significantly abolished by Pdcd4 deficiency in mice (Fig. 3A), as determined by mRNA (Fig. 3B), Western blot (Fig. 3C), and IHC-staining analyses (Fig. 3D). In vitro, we used the following approaches to mimic hypoxic conditions in NRK-52E cells: (1) oxygen-glucose deprivation (OGD, Fig. 3E); and (2) glucose-free medium with antimycin A (AA)/2-deoxyglucose (2-DG) for ATP depletion (90 min, anoxia). Subsequently, we changed the glucose-replete complete growth medium (recovery) and CoCl2 treatment (Supporting Information Fig. S3). All manipulations significantly induced the expression of PDCD4 and FGR. Gene silencing of Pdcd4 attenuated hypoxia-induced FGR expression (Fig. 3F), indicating that PDCD4 may positively mediate FGR expression.

### 3.4. PDCD4 contributes to hypoxia-induced inflammatory responses and cell death in NRK-52E cells via regulating FGR expression

Overexpression of PDCD4 (Fig. 4A) aggravated hypoxia-enhanced production of pro-inflammatory mediators (Fig. 4C), as well as apoptosis (Fig. 4D) accompanied by increased caspase-3 activity (Fig. 4E), which were counteracted by Fgr knockdown (Fig. 4B). Luciferase activity assays further confirmed that PDCD4 enhanced Fgr transcription (Fig. 4F). Luciferase activity assays also showed that siRNA-Pdcd4 decreased Fgr transcription, which can be recovered by siRNA-Daxx under OGD conditions, indicating that DAXX may regulate transcription of FGR (Supporting Information Fig. S4). We also examined the expression level of DAXX in the kidneys from Pdcd4−/− mice and found that Pdcd4 deficiency dramatically increased the expression of DAXX under AKI conditions (Fig. S4). However, further studies are needed to confirm these results.

### 3.5. PDCD4 positively regulates FGR-mediated NOTCH1 signaling through STAT3 activation

We found that IRI-induced NOTCH1 expression was significantly abolished by Pdcd4 deficiency in mice, as revealed via microarray analysis (Fig. 3A), which was further confirmed by mRNA (Fig. 5A), Western blot (Fig. 5B), and IHC (Supporting Information Fig. S5) analyses. In vitro, overexpression of Pdcd4 increased hypoxia-induced the production of NOTCH1 which was counteracted by Fgr knockdown (Fig. 5C) in NRK-52E cells, indicating that NOTCH1 may be a downstream target of the PDCD4/FGR pathway. Considering that STAT3 was identified as a potential transcription factor regulated by SRC kinase22,23 and that inhibition of STAT3 protects against renal IRI24, we next investigated whether PDCD4 regulates the FGR/NOTCH1 signaling pathway via STAT3. We found that hypoxia-induced STAT3 activation as indicated by increased levels of phospho-STAT3 at

---

**Figure 3** PDCD4 positively regulates FGR expression. (A) Representative heatmap of gene expression levels in the kidneys from mice with IRI, by multiplexed qRT-PCR arrays. (B) Summarized data showing the mRNA levels of Fgr in the kidneys from mice with renal IRI (n = 6). (C) Representative Western blots and summarized data showing the protein levels of FGR in the kidneys from mice with renal IRI (n = 6). (D) Representative photomicrographs of FGR IHC staining in the kidneys from mice with renal IRI. (E) Representative Western blot documents and summarized data showing the protein levels of PDCD4 and FGR in NRK-52E cells under OGD conditions (n = 3). (F) Representative Western blot gel documents and summarized data showing the protein levels of PDCD4 and FGR in NRK-52E cells under OGD conditions by gene silencing of Pdcd4 (n = 3). All data are displayed as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA.
both serine (residue 727) and tyrosine (residue 705) sites (Fig. 5D), as well as by nuclear translocation of STAT3 (Fig. 5E), and increased NOTCH1 levels that were further enhanced by Fgr overexpression. Importantly, all of these FGR-mediated effects were counteracted by the STAT3 phosphorylation inhibitor, HO-3867 (Fc tagged, 10 μmol/mL, Selleckchem, Houston, TX, USA) in NRK-52E cells. Similarly, gene silencing of Fgr decreased phospho-STAT3 levels and the expression of NOTCH1 (Supporting Information Fig. S6), indicating that FGR mediated NOTCH1 signaling via STAT3 phosphorylation.

3.6. In vivo gene overexpression of Fgr counteracts the alleviated renal injury and inflammatory responses in Pdcd4⁻/⁻ ischemic mice

To further investigate whether FGR acts as a key regulator linking PDCD4 and inflammatory responses in AKI, a recombinant adeno-associated virus (rAAV) serotype 9 harboring Fgr was delivered into mice by means of intraparenchymal injections. Intense green fluorescence was seen in the kidneys at one month after intrarenal delivery of the AAV encoding Fgr-Gfp, but not in the kidneys from control mice injected with normal saline (Supporting Information Fig. S7A). Moreover, Western blot analysis also confirmed the FGR overexpression efficiency (Fig. S7B). FGR counteracted the alleviated kidney injury in Pdcd4⁻/⁻ ischemic mice, as evidenced by increased serum creatinine (Fig. 6A) and BUN (Fig. 6B), deteriorated morphologic injury (Fig. 6C and D), enhanced cell death (Fig. 6E and F), and increased inflammatory responses by augmenting levels of pro-inflammatory mediators (Fig. 6G), as well as enhanced macrophage and neutrophil infiltration in the kidneys from mice with IRI. Importantly, downregulation of NOTCH1 in Pdcd4⁻/⁻ ischemic mice was partially rescued by Fgr overexpression (Fig. 6H).

3.7. Ponatinib partially rescues renal IRI injury in mice

Pharmacologically, we tested whether ponatinib, a third-generation of pan tyrosine kinase inhibitor (TKI), could alleviate renal IRI in mice. We found that ponatinib dramatically alleviated renal IRI, as evidenced by reduced serum creatinine (Fig. 7A) and BUN (Fig. 7B), as well as attenuated morphologic injury (Fig. 7C and D), and cell death revealed by TUNEL staining (Fig. 7E and F). However, ponatinib had no significant effect on the renal function of Pdcd4⁻/⁻ ischemic mice, further confirming the involvement of FGR in PDCD4-mediated signaling in AKI.

3.8. Pdcd4 deficiency protects against cisplatin-induced AKI

To determine the broad implications of PDCD4 signaling in AKI, we further investigated whether PDCD4 also played a detrimental role in mice with cisplatin-induced AKI. We found that PDCD4, FGR and NOTCH1 expression levels were increased in the kidneys from mice receiving cisplatin treatments (Fig. 8A and B). Furthermore, Pdcd4 deficiency ameliorated renal dysfunction (Fig. 8C and D), histologic lesions (Fig. 8E and F) and cell death (Fig. 8G and H). Additionally, cisplatin-induced increase in the expression levels of FGR and NOTCH1 (Fig. 8I) were attenuated by Pdcd4 deficiency. In vitro, cisplatin-induced PDCD4 expression and activation of the FGR/NOTCH1 signaling pathway were observed. Finally, gene silencing of Pdcd4 alleviated cisplatin-mediated inflammation and apoptosis in NRK-52E cells (Supporting Information Fig. S9). Taken together, these results indicate that PDCD4-mediated activation of the FGR/NOTCH1 signaling...
pathway may be a common response in AKI. Using ponatinib or other drugs targeting this pathway may have important therapeutic implications for treating AKI.

4. Discussion

Although there has been significant progress in better understanding the structure and function of PDCD4, the contributions and mechanisms of PDCD4 in AKI have remained unknown. In the present study, by using two separate murine AKI models including IRI and cisplatin-induced AKI, we found that PDCD4 deficiency markedly ameliorated renal dysfunction, histologic lesions, and inflammatory responses in AKI mice. We also confirmed the upregulation of PDCD4 in the kidneys from patients with biopsy-confirmed acute tubular necrosis from a retrospective cohort study. We further identified that PDCD4 served as a positive regulator of AKI, at least in part, by mediating FGR/NOTCH1-mediated apoptosis and inflammation. Importantly, the potent FGR activity inhibitor, ponatinib, dramatically prevented AKI in mice, providing promising evidence for its therapeutic potential in ameliorating AKI.

PDCD4 is regulated by a number of mechanisms, most notably as a target of miR-21. Some previous studies have demonstrated ischemic-induced and xenon-preconditioning-induced upregulation of miR-21, which mediates renal-protective effects through PDCD4 [4,26]. Similarly, the upregulation of miR-21 by ghrelin can ameliorate IR-induced AKI [27]. However, another study has indicated that overexpression of miR-21 alone is not sufficient to prevent TEC death following ischemia [28]. Also, there are many studies that have shown RNA-binding proteins (e.g., HuR), are upregulated in AKI [29,30], and can increase the steady-state of PDCD4 mRNA and protein levels [30,31]. Recently, PDCD4 has been found in the lncRNA H19/miR-21/PDCD4 competing endogenous RNA network (ceRNET) and H19 competitively binds with miR-21 to facilitate PDCD4 expression in mouse retinas during I/R, indicating the important role of PDCD4 in I/R injury [32]. Because the post-transcriptional...
regulation of PDCD4 and the physiological mechanisms of AKI are complex, investigations of miR-21 or HuR can not fully explain the expression pattern and function of PDCD4 in AKI. Therefore, in the present study, we first confirmed the upregulation of PDCD4 in AKI mice, as well as in the kidneys from patients with biopsy-confirmed acute tubular necrosis indicating that PDCD4 may play an important role in AKI. Then we used the Pdcd4−/− knockout mice to reveal that PDCD4 exacerbated AKI through increasing TEC death and inflammation. Moreover, we explored the detailed mechanisms of PDCD4 in AKI mice and found a positive correlation between PDCD4 and FGR levels in the kidney.

FGR is a member of the SRC family kinases (SFKs), which are the largest family of non-receptor protein tyrosine kinases and include SRC, LCK, FYN, YES, FGR, BLK, LYN and FRK. SFKs can phosphorylate a variety of cellular proteins on tyrosine residues, leading to the activation of protein targets in response to different stimuli, thereby regulating multiple cellular events including cellular movement, differentiation, proliferation, survival, and apoptosis. Emerging evidence has shown that SFKs are pivotal mediators in the regulation of renal function, although the role of some SRKs remains controversial under different renal pathological conditions. In the present study, we observed changes in SFKs by microarray analysis in the kidneys from ischemic mice. Among SFKs, FGR was significantly induced in the kidneys from mice with renal IRI. In addition to FGR contributing to tumor development by preventing programmed cell death and promoting cellular migration, FGR also mediates inflammatory responses. Dysregulation of FGR is known to result in defective eosinophil recruitment to the lung during allergic airway inflammation and reduced plaque growth and stability by blunting monocyte recruitment. In the present study, we found that FGR was significantly induced in TEC in the kidneys from mice with AKI. Gene silencing of Fgr decreased hypoxia-induced production of pro-inflammatory mediators and apoptosis in proximal tubule epithelial cells. Surprisingly, we found that FGR induced apoptosis in proximal tubule epithelial cells, rather than inhibiting apoptosis in tumor cells. These opposite effects may depend on different cell types or different disease states. Furthermore, we verified that Pdcd4 deficiency markedly inhibited AKI-induced FGR expression in the kidney, suggesting that FGR signaling is one of the critical signal transduction pathways that link PDCD4 with the induction of AKI. Although we did not explore the detailed mechanisms by which PDCD4 mediates FGR expression in AKI, PDCD4 has been well documented to act as a regulator of gene expression through

**Figure 6** *In vivo* gene overexpression of Fgr counteracts the alleviated renal injury and inflammatory responses in Pdcd4−/− ischemic mice. (A) Serum creatinine (Scr) concentrations in different groups of mice (n = 8). (B) BUN levels in different groups of mice (n = 8). (C) Representative micrographs showing the morphologies of the kidneys from different groups of mice. (D) Quantitative assessment of tubular damage (n = 8). (E) *In situ* terminal TUNEL assays were performed to assess renal cell death. Nuclei were revealed using DAPI staining. (F) Quantitative assessment of the number of dead cells (numbers per high-power field [HPF]; n = 8). (G) The mRNA levels of pro-inflammatory mediators including Il-1β, Il-6, Tnf-α, and Mcp-1 in the kidneys from different groups of mice (n = 8). (H) Representative Western blots and summarized data showing the protein levels of NOTCH1 in the kidneys from different groups of mice (n = 4). All data are displayed as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA.
influencing both transcription and translation. Recently, PDCD4 has been identified as a novel interaction partner of death domain associated protein (DAXX) and stimulates the degradation of DAXX. DAXX is a well-established transcriptional repressor that binds to numerous transcription factors, including members of the PAX and P53 families, as well as C/EBPb, ETS1, SMAD4, glucocorticoid receptors and androgen receptors. In the present study, our results indicate that DAXX may be a potential transcription regulator of FGR. However, further studies are needed to confirm these results.

It is well known that the NOTCH pathway is an evolutionarily conserved intercellular signaling pathway responsible for the control of cell fate and tissue morphogenesis during development and disease. The activation of tubular epithelial NOTCH1 signaling has been shown to be prolonged in the aging kidney after IRI. In the present study, we observed changes in NOTCH family proteins, especially NOTCH1, in the kidneys from ischemic mice and further confirmed that FGR mediated NOTCH1 expression, at least in part, by activation of signal transducer and activator of transcription 3 (STAT3). STAT3 has long been recognized for its increased transcriptional activity in cancers and autoimmune disorders. Recently, STAT3 has received increased attention due to its elucidated role in the progression of kidney disease. STAT3 is aberrantly activated in the kidney from autosomal-dominant polycystic kidney disease (ADPKD) patients and in PKD mouse models. Recent studies have also shown that interleukin-6 (IL-6) contributes to the increase in fibroblast growth factor 23 (FGF23) levels through STAT3 phosphorylation in both acute and chronic kidney disease. In the present study, we found that FGR-mediated STAT3 phosphorylation, thereby resulting in increased Notch1 transcription.

Mechanistically, previous studies have shown that phosphorylated STAT3 enters the nucleus, binds to the Notch1’s promotor, and enhances the Notch1 transcription.

Given that FGR plays a vital role in PDCD4-mediated activation of the NOTCH1 signaling pathway in AKI, we further tested whether ponatinib-mediated inhibition of this signaling protects against AKI. Ponatinib (trade name Iclusig), is an orally active multi-tyrosine kinase inhibitor and is currently approved by the U.S. Food and Drug Administration for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Due to the multi-targeted characteristics of ponatinib, further studies have demonstrated its ability to target other important tyrosine kinases (e.g., SRC and RET) in other human malignancies. Importantly, we found that ponatinib dramatically alleviated renal IRI in wild-type mice. Our data also indicated that ponatinib had a significant inhibitory effect on the activity of FGR rather than that of SRC or RET (Supporting Information Fig. S10). The reason for this phenomenon may be due to the PDCD4/FGR/NOTCH1 pathway being dramatically activated under AKI conditions. These results further suggest that the therapeutic effect of ponatinib mainly depends on its inhibition of FGR activity. Importantly, in our present study ponatinib had no further effect on the regulation of renal function in Pdcd4 ischemic mice, indicating the involvement of FGR in PDCD4-mediated renal function in AKI. These studies provide compelling evidence that ponatinib or other drugs targeting FGR may be used as therapeutic agents for the treatment of AKI. It has been reported that the dose of ponatinib is correlated with the incidence of adverse events. Meanwhile, compared with features of anti-tumor treatments, the usage period and dosage of ponatinib to treat AKI are much shorter and lower, which may help to circumvent long-term adverse reactions and further support the use of ponatinib in treating AKI patients. Hence, further studies...
are needed to investigate whether other chemical drugs targeting FGR such as saracatinib (AZD0530), have similar therapeutic effects in AKI.

Collectively, the findings of our present study provide direct evidence showing that FGR/NOTCH1 is one of the critical signal transduction pathways that links PDCD4 to AKI in mice. Therefore pharmacological targeting of PDCD4 signaling pathways at multiple levels, such as via inhibition of PDCD4 or FGR activity, may represent novel therapeutic strategies for the treatment of AKI.

5. Conclusions

We found that PDCD4 served as an important regulator of AKI in mice, at least partly via FGR/NOTCH1-mediated tubular apoptosis and inflammation. Using ponatinib-mediated
pharmacologic targeting of this pathway may hold therapeutic potential for mitigating AKI.

Acknowledgments

We thank Fan Yi for help in designing the study and revising the manuscript. This study was supported by the National Natural Science Foundation of China (81770726, 81970580, 81670629 and 81600570); and the Key Technology Research and Development Program of Shandong (2017GSF218095, China).

Author contributions

Yan Zhang and Wei Tang designed the study. Xu Jing, Dandan Ren and Fei Gao carried out most of the experiments. Xiao Wu contributed to the preparation of human kidney specimens. Ye Chen interpreted the results. Yue Han and Qingsheng Han contributed to data collection. Liang Li and Xiaojie Wang contributed to the preparation of the figures. All authors contributed to data analysis and the preparation, writing and final approval of the manuscript.

Conflicts of interest

All authors declare no competing interests.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2020.10.024.

References

1. Lameire NH, Bagga A, Cruz D, de Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: An increasing global concern. Lancet 2013; 382:170–9.

2. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol 2014;25:2689–701.

3. Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006;25:6101–12.

4. Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F, et al. Frequent loss of PDCD4 expression in human glioma: Possible role in the tumorigenesis of glioma. Oncol Rep 2007;17:123–8.

5. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell 2009;101:309–17.

6. Waters LC, Veverka V, Bohn M, Schmedt T, Choong PT, Muskett FW, et al. Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A. Oncogene 2007; 26:4941–50.

7. Waters LC, Strong SL, Ferlemann E, Oka O, Muskett FW, Veverka V, et al. Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: Molecular mechanisms of a tumor suppressor. J Biol Chem 2011; 286:17270–80.

8. Xu X, Jiao X, Song N, Luo W, Liang M, Ding X, et al. Role of miR21 on vascular endothelial cells in the protective effect of renal delayed ischemic preconditioning. Mol Med Rep 2017;16:2627–35.

9. Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo OE, et al. Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Mol Cell Biol 2012;32:1818–29.

10. Wang L, Jiang Y, Song X, Guo C, Zhu F, Wang X, et al. Pdcd4 deficiency enhances macrophage lipoproteinophagy and attenuates foam cell formation and atherosclerosis in mice. Cell Death Dis 2016;7:e2055.

11. Jiang Y, Gao Q, Wang LY, Ma T, Zhu FL, Wang Q, et al. Deficiency of programmed cell death 4 affects the balance of T cell subsets in hyperlipidemic mice. Mol Immunol 2019;112:387–93.

12. van den Bosch MW, Palsson-McDermott E, Johnson DS, O’Neill LA. LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production. J Biol Chem 2014; 289:22980–90.

13. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O’Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141–7.

14. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008;105:6392–7.

15. Murea M, Park JK, Sharma S, Kato H, Gruenwald A, Niranjan T, et al. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int 2010;78:514–22.

16. Liu M, Liang K, Zhen J, Zhou M, Wang X, Wang Z, et al. Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling. Nat Commun 2017;8:413.

17. Kopan R, Ilagan MX. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 2009;137:216–33.

18. Zhou M, Tang W, Fu Y, Xu X, Wang Z, Lu Y, et al. Progranulin protects against renal ischemia/reperfusion injury in mice. Kidney Int 2015;87:918–20.

19. Wang X, Liu J, Zhen J, Zhang C, Wang Q, Liu G, et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney Int 2014;86:712–25.

20. Shang J, Zhang Y, Jiang Y, Li Z, Duan Y, Wang L, et al. NOD2 promotes endothelial-to-mesenchymal transition of glomerular endothelial cells via MEK/ERK signaling pathway in diabetic nephropathy. Biochem Biophys Res Commun 2017;484:435–41.

21. Rocca CJ, Ur SN, Harrison F, Chequini S. rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: Conclusion of a comparative study. Gene Ther 2014;21:618–28.

22. Chuang PY, He JC. JAK/STAT signaling in renal diseases. Kidney Int 2010;78:231–4.

23. Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, Gong R, et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 2012;23:854–67.

24. Li R, Yang N, Zhang L, Huang Y, Zhang R, Wang F, et al. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol 2007;27:580–9.

25. Kim J, Park RY, Chen JK, Kim J, Jeong S, Ohn T. Splicing factor SRSF3 represses the translation of programmed cell death 4 mRNA by associating with the 5'-UTR region. Cell Death Differ 2014;21:481–90.

26. Jia P, Teng J, Zou J, Fang Y, Wu X, Liang M, et al. XenoN protects against septic acute kidney injury via miR-21 target signaling pathway. Crit Care Med 2015;43:e250–9.

27. Zhang W, Shu L. Upregulation of miR-21 by ghrelin ameliorates ischemia/reperfusion-induced acute kidney injury by inhibiting inflammation and cell apoptosis. DNA Cell Biol 2016;35:417–25.

28. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A 2010;107:14339–44.

29. Fang W, Wang Z, Li Q, Wang X, Zhang Y, Sun Y, et al. Gpr97 ex-acerbates AKI by mediating Sema3A signaling. J Am Soc Nephrol 2018;29:1475–89.

30. Poria DK, Guha A, Nandi I, Ray PS. RNA-binding protein HuR se-questers microRNA-21 to prevent translation repression of proinflammtory tumor suppressor gene programmed cell death 4. Oncogene 2016;35:1703–15.
31. Wigington CP, Jung J, Rye EA, Belauret SL, Phlipot AM, Feng Y, et al. Post-transcriptional regulation of programmed cell death 4 (PDCD4) mRNA by the RNA-binding proteins human antigen R (HuR) and T-cell intracellular antigen 1 (TIA1). J Biol Chem 2015; 290:3468–3477.

32. Pan W, Su W, Zhang Y, Li Z, Deng C, Li J, et al. LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. Cell Death Differ 2020;27:176–91.

33. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene 2004;23:7906–9.

34. Vines CM, Potter JW, Xu Y, Geahlen RL, Costello PS, Tybulewicz VL, et al. Inhibition of beta 2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr. Immunity 2001;15:507–19.

35. Tuguzbaeva G, Yue E, Chen X, He L, Li X, Ju J, et al. PEP06 peptide 30 is a novel cluster-dissociating agent inhibiting v integ- rin/FAK/Src signaling in oral squamous cell carcinoma cells. Acta Pharm Sin B 2019;9:1163–73.

36. Havasi A, Wang Z, Gall JM, Spaderna M, Suri V, Canlas E, et al. Hsp27 inhibits sublethal, Src-mediated renal epithelial cell injury. Am J Physiol Ren Physiol 2009;297:F760–8.

37. Xiong C, Zang X, Zhou X, Liu L, Masucci MV, Tang J, et al. PEP06 polypeptide 30 is a novel cluster-dissociating agent inhibiting a v integrin/Fgr/Src signaling in oral squamous cell carcinoma cells. Acta Pharm Sin B 2019;9:1163–73.

38. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clin Canc Res 2011;17:1713–21.

39. Link DC, Zutter M. The proto-oncogene c-fgr is expressed in diabetic nephropathy in mice. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 2013;62:3874–86.

40. Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, et al. The cleaved cytoplasmic tail of polycystin-1 regulates Src-mediated renal epithelial cell injury. Am J Physiol Ren Physiol 2010;299:F1–F8.

41. Zhang H, Huang L, Tao L, Zhang J, Wang F, Zhang X, et al. Seocalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells through upregulating c-Jun expression. Acta Pharm Sin B 2019;9:516–25.

42. Yu H, Pardoll D, Jove R. STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 2010;78:257–68.

43. Wang X, Wei X, Pang Q, Yi F. Histone deacetylases and their inhibitors: Molecular mechanisms and therapeutic implications in diabetes mellitus. Acta Pharm Sin B 2012;2:387–95.

44. Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, et al. The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol 2014;25:1737–48.

45. Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int 2018;94:315–25.

46. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 2013;288:26167–76.

47. Tan FH, Putoczki TL, Styli SS, Luwor RB, Ponatinib: A novel multityrosine kinase inhibitor against human malignancies. Oncotargets Ther 2019;12:635–45.

48. Fava C, Saglio G. Ponatinib for chronic myeloid leukemia: Future perspectives. Lancet Oncol 2016;17:546–7.